Lineage Non Current Liabilities Total from 2010 to 2025
| LCTX Stock | USD 0.49 0.01 2.00% |
Non Current Liabilities Total | First Reported 1992-03-31 | Previous Quarter 17.9 M | Current Value 22.2 M | Quarterly Volatility 8.1 M |
Check Lineage Cell financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lineage Cell's main balance sheet or income statement drivers, such as Depreciation And Amortization of 922.5 K, Interest Expense of 6 M or Total Revenue of 10 M, as well as many indicators such as Price To Sales Ratio of 10.06, Dividend Yield of 0.0015 or PTB Ratio of 1.37. Lineage financial statements analysis is a perfect complement when working with Lineage Cell Valuation or Volatility modules.
Lineage | Non Current Liabilities Total |
Latest Lineage Cell's Non Current Liabilities Total Growth Pattern
Below is the plot of the Non Current Liabilities Total of Lineage Cell Therapeutics over the last few years. It is Lineage Cell's Non Current Liabilities Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lineage Cell's overall financial position and show how it may be relating to other accounts over time.
| Non Current Liabilities Total | 10 Years Trend |
|
Non Current Liabilities Total |
| Timeline |
Lineage Non Current Liabilities Total Regression Statistics
| Arithmetic Mean | 11,149,131 | |
| Geometric Mean | 5,433,257 | |
| Coefficient Of Variation | 107.13 | |
| Mean Deviation | 10,017,224 | |
| Median | 5,751,000 | |
| Standard Deviation | 11,944,306 | |
| Sample Variance | 142.7T | |
| Range | 36.3M | |
| R-Value | 0.76 | |
| Mean Square Error | 65.6T | |
| R-Squared | 0.57 | |
| Significance | 0.0007 | |
| Slope | 1,895,520 | |
| Total Sum of Squares | 2140T |
Lineage Non Current Liabilities Total History
About Lineage Cell Financial Statements
Lineage Cell investors use historical fundamental indicators, such as Lineage Cell's Non Current Liabilities Total, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Lineage Cell. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Non Current Liabilities Total | 22.2 M | 23.3 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Lineage Stock Analysis
When running Lineage Cell's price analysis, check to measure Lineage Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lineage Cell is operating at the current time. Most of Lineage Cell's value examination focuses on studying past and present price action to predict the probability of Lineage Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lineage Cell's price. Additionally, you may evaluate how the addition of Lineage Cell to your portfolios can decrease your overall portfolio volatility.